NAVB Thx Validate:ChemoThx's like paclitaxel show potential as M1/M2 immuno in cancer | NAVB Message Board Posts


Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  40336 of 40752  at  9/21/2023 5:21:00 PM  by

moneyonomics

The following message was updated on 9/21/2023 6:38:43 PM.

NAVB Thx Validate:ChemoThx's like paclitaxel show potential as M1/M2 immuno in cancer

   
A joint Germany-China study on M1/M2, etc immunoactivation potential by chemotherapeutics like paclitaxel  in cancer treatment adds validation to Navidea pre clinical trial for TAMS reprogramming using paclitaxel
 
 
 The abstract, “Synthetic CD206 Targeted Constructs Carrying Paclitaxel or Novel Bisphosphonate Payloads Alter Macrophages Towards Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the Efficacy of anti-CTLA4 in CT26 Tumors” (Abstract #1161), will be presented as a poster on November 10, 9 am to 9 pm in the conference center’s poster hall. Further details of the abstract will be announced in a future press release once the meeting embargo is lifted.